JP2021502408A - 炎症性皮膚疾患を治療するための複合医薬組成物 - Google Patents
炎症性皮膚疾患を治療するための複合医薬組成物 Download PDFInfo
- Publication number
- JP2021502408A JP2021502408A JP2020544101A JP2020544101A JP2021502408A JP 2021502408 A JP2021502408 A JP 2021502408A JP 2020544101 A JP2020544101 A JP 2020544101A JP 2020544101 A JP2020544101 A JP 2020544101A JP 2021502408 A JP2021502408 A JP 2021502408A
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- tofacitinib
- chrysabolol
- inflammatory skin
- dermatitis
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 20
- 201000004624 Dermatitis Diseases 0.000 title claims abstract description 15
- 239000004012 Tofacitinib Substances 0.000 claims abstract description 27
- 229960001350 tofacitinib Drugs 0.000 claims abstract description 27
- UJLAWZDWDVHWOW-YPMHNXCESA-N tofacitinib Chemical compound C[C@@H]1CCN(C(=O)CC#N)C[C@@H]1N(C)C1=NC=NC2=C1C=CN2 UJLAWZDWDVHWOW-YPMHNXCESA-N 0.000 claims abstract description 27
- 239000002131 composite material Substances 0.000 claims abstract description 11
- 239000003814 drug Substances 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims abstract description 5
- 206010061218 Inflammation Diseases 0.000 claims description 10
- 201000008937 atopic dermatitis Diseases 0.000 claims description 10
- 230000004054 inflammatory process Effects 0.000 claims description 10
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 206010012442 Dermatitis contact Diseases 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- 208000010247 contact dermatitis Diseases 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 5
- 206010012434 Dermatitis allergic Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 208000008742 seborrheic dermatitis Diseases 0.000 claims description 4
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 239000006071 cream Substances 0.000 claims description 3
- 239000003599 detergent Substances 0.000 claims description 3
- 239000000839 emulsion Substances 0.000 claims description 3
- 239000004088 foaming agent Substances 0.000 claims description 3
- 229940040145 liniment Drugs 0.000 claims description 3
- 239000000865 liniment Substances 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 9
- 239000000203 mixture Substances 0.000 abstract description 4
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 238000010586 diagram Methods 0.000 abstract 1
- 208000003251 Pruritus Diseases 0.000 description 6
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 5
- 230000007803 itching Effects 0.000 description 5
- 230000004163 JAK-STAT signaling pathway Effects 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 206010014025 Ear swelling Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 3
- 108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- PHEDXBVPIONUQT-RGYGYFBISA-N phorbol 13-acetate 12-myristate Chemical compound C([C@]1(O)C(=O)C(C)=C[C@H]1[C@@]1(O)[C@H](C)[C@H]2OC(=O)CCCCCCCCCCCCC)C(CO)=C[C@H]1[C@H]1[C@]2(OC(C)=O)C1(C)C PHEDXBVPIONUQT-RGYGYFBISA-N 0.000 description 3
- 239000002644 phorbol ester Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 101000845170 Homo sapiens Thymic stromal lymphopoietin Proteins 0.000 description 2
- 102000014150 Interferons Human genes 0.000 description 2
- 108010050904 Interferons Proteins 0.000 description 2
- 240000001307 Myosotis scorpioides Species 0.000 description 2
- 229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 2
- 102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 2
- 108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 2
- 102100031294 Thymic stromal lymphopoietin Human genes 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 210000005069 ears Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 229940079322 interferon Drugs 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 239000002587 phosphodiesterase IV inhibitor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
- 101000997835 Homo sapiens Tyrosine-protein kinase JAK1 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 229940116839 Janus kinase 1 inhibitor Drugs 0.000 description 1
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102100033438 Tyrosine-protein kinase JAK1 Human genes 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- USZAGAREISWJDP-UHFFFAOYSA-N crisaborole Chemical compound C=1C=C2B(O)OCC2=CC=1OC1=CC=C(C#N)C=C1 USZAGAREISWJDP-UHFFFAOYSA-N 0.000 description 1
- 229950008199 crisaborole Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 238000009521 phase II clinical trial Methods 0.000 description 1
- 230000025915 regulation of apoptotic process Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 239000003871 white petrolatum Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/69—Boron compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
SPFグレードのICRマウス(雄、18〜22g)を、体重に応じて、異なる配合比率の化合物組とモデル組に分け、各組に10匹のマウスが割り当てられる。実験対象の薬物を20μLの溶媒DMSOで溶解させ、具体的な組分け番号は下記のとおりである。
各組のマウスに対して、右耳の前後にいずれもホルボールエステル20ul(5μg/20ul/耳)を塗抹してモデリングし、左耳に20μlの溶媒(アセトン)を塗抹し、モデル組以外に、各投薬組のマウスの右耳は、モデリング前30分、モデリング後15分に、対応する薬剤を20μl/耳で塗抹した。モデリングの6時間後に、シックネスゲージで耳腫脹の程度を測り、炎症の指標とした。また動物を殺し、耳を切り落とし、6mmの穿孔機で穿孔し、切り落とされた耳の重量を量り、腫脹の程度(重量)を計算した。
軟膏剤、調合量は下記のとおりである。
(付記1)
薬学的活性成分と薬学的に許容される担体とを含有し、前記薬学的活性成分はトファシチニブとクリサボロールとで構成されることを特徴とする、複合医薬組成物。
前記トファシチニブと前記クリサボロールの重量比は、1:8〜8:1である付記1に記載の複合医薬組成物。
炎症性皮膚疾患の治療用の薬物を調製するための付記1または2に記載の複合医薬組成物の使用。
炎症性皮膚疾患が、アレルギー性皮膚炎、蕁麻疹、アトピー性皮膚炎、脂漏性皮膚炎または接触性皮膚炎である、付記3に記載の使用。
炎症性皮膚疾患は、乾癬または全身性エリテマトーデスによって引き起こされる皮膚の炎症反応である、付記3に記載の使用。
剤形は外用製剤である、付記1または2に記載の複合医薬組成物。
外用製剤の剤形は乳剤、クリーム剤、ゲル剤、発泡剤、粉剤、リニメント剤、洗剤、噴霧剤またはパッチ剤である、付記6に記載の複合医薬組成物。
Claims (7)
- 薬学的活性成分と薬学的に許容される担体とを含有し、前記薬学的活性成分はトファシチニブとクリサボロールとで構成されることを特徴とする、複合医薬組成物。
- 前記トファシチニブと前記クリサボロールの重量比は、1:8〜8:1である請求項1に記載の複合医薬組成物。
- 炎症性皮膚疾患の治療用の薬物を調製するための請求項1または2に記載の複合医薬組成物の使用。
- 炎症性皮膚疾患が、アレルギー性皮膚炎、蕁麻疹、アトピー性皮膚炎、脂漏性皮膚炎または接触性皮膚炎である、請求項3に記載の使用。
- 炎症性皮膚疾患は、乾癬または全身性エリテマトーデスによって引き起こされる皮膚の炎症反応である、請求項3に記載の使用。
- 剤形は外用製剤である、請求項1または2に記載の複合医薬組成物。
- 外用製剤の剤形は乳剤、クリーム剤、ゲル剤、発泡剤、粉剤、リニメント剤、洗剤、噴霧剤またはパッチ剤である、請求項6に記載の複合医薬組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810637196.3A CN108992454B (zh) | 2018-06-20 | 2018-06-20 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
CN201810637196.3 | 2018-06-20 | ||
PCT/CN2019/086094 WO2019242422A1 (zh) | 2018-06-20 | 2019-05-09 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2021502408A true JP2021502408A (ja) | 2021-01-28 |
JP7083118B2 JP7083118B2 (ja) | 2022-06-10 |
Family
ID=64601378
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020544101A Active JP7083118B2 (ja) | 2018-06-20 | 2019-05-09 | 炎症性皮膚疾患治療薬および炎症性皮膚疾患の治療薬を調製するための薬学的活性成分の使用 |
Country Status (6)
Country | Link |
---|---|
US (1) | US11318151B2 (ja) |
EP (1) | EP3685840B1 (ja) |
JP (1) | JP7083118B2 (ja) |
CN (1) | CN108992454B (ja) |
ES (1) | ES2911110T3 (ja) |
WO (1) | WO2019242422A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108992454B (zh) * | 2018-06-20 | 2020-06-02 | 合肥医工医药股份有限公司 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
CN113712977A (zh) * | 2020-05-25 | 2021-11-30 | 南京帝昌医药科技有限公司 | 一种克立硼罗外用制剂其制备方法及用途 |
WO2022022434A1 (zh) * | 2020-07-27 | 2022-02-03 | 杭州和正医药有限公司 | 含托法替尼药学上可接受的盐的药物组合物、制剂及应用 |
WO2024030600A1 (en) * | 2022-08-05 | 2024-02-08 | Incyte Corporation | Treatment of urticaria using jak inhibitors |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011515344A (ja) * | 2008-01-09 | 2011-05-19 | アナコール ファーマシューティカルズ,インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
JP2012219099A (ja) * | 2011-04-08 | 2012-11-12 | Pfizer Inc | 結晶性ピロロ[2,3−d]ピリミジン化合物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008520612A (ja) * | 2004-11-24 | 2008-06-19 | ノバルティス アクチエンゲゼルシャフト | JAK阻害剤およびBcr−Abl、Flt−3、FAKまたはRAFキナーゼ阻害剤のうち少なくとも1個の組合せ |
GB0605691D0 (en) * | 2006-03-21 | 2006-05-03 | Novartis Ag | Organic Compounds |
JP6041823B2 (ja) * | 2013-03-16 | 2016-12-14 | ファイザー・インク | トファシチニブの経口持続放出剤形 |
CN106146508A (zh) * | 2015-03-19 | 2016-11-23 | 浙江导明医药科技有限公司 | 优化的联合用药及其治疗癌症和自身免疫疾病的用途 |
ES2858311T3 (es) * | 2015-11-30 | 2021-09-30 | Anacor Pharmaceuticals Inc | Formulaciones farmacéuticas tópicas para el tratamiento de afecciones relacionadas con inflamación |
CN108047261B (zh) * | 2018-01-10 | 2020-12-18 | 苏州旺山旺水生物医药有限公司 | 一种克立硼罗的制备方法 |
CN108992454B (zh) * | 2018-06-20 | 2020-06-02 | 合肥医工医药股份有限公司 | 一种治疗皮肤炎症性疾病的复方药物组合物 |
-
2018
- 2018-06-20 CN CN201810637196.3A patent/CN108992454B/zh active Active
-
2019
- 2019-05-09 WO PCT/CN2019/086094 patent/WO2019242422A1/zh unknown
- 2019-05-09 EP EP19822182.2A patent/EP3685840B1/en active Active
- 2019-05-09 US US16/761,996 patent/US11318151B2/en active Active
- 2019-05-09 ES ES19822182T patent/ES2911110T3/es active Active
- 2019-05-09 JP JP2020544101A patent/JP7083118B2/ja active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2011515344A (ja) * | 2008-01-09 | 2011-05-19 | アナコール ファーマシューティカルズ,インコーポレイテッド | 抗炎症剤としてのホウ素含有小分子 |
JP2012219099A (ja) * | 2011-04-08 | 2012-11-12 | Pfizer Inc | 結晶性ピロロ[2,3−d]ピリミジン化合物 |
Non-Patent Citations (1)
Title |
---|
日本臨床(増刊) 最新関節リウマチ学, vol. 72(suppl.3), JPN6021048093, pages 741 - 746, ISSN: 0004657725 * |
Also Published As
Publication number | Publication date |
---|---|
US20200352965A1 (en) | 2020-11-12 |
EP3685840A1 (en) | 2020-07-29 |
ES2911110T3 (es) | 2022-05-17 |
JP7083118B2 (ja) | 2022-06-10 |
EP3685840B1 (en) | 2022-01-26 |
EP3685840A4 (en) | 2020-11-25 |
CN108992454B (zh) | 2020-06-02 |
CN108992454A (zh) | 2018-12-14 |
WO2019242422A1 (zh) | 2019-12-26 |
US11318151B2 (en) | 2022-05-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7083118B2 (ja) | 炎症性皮膚疾患治療薬および炎症性皮膚疾患の治療薬を調製するための薬学的活性成分の使用 | |
EP3435973B1 (en) | Apremilast pharmaceutical compositions | |
CA2875052C (en) | Method for treating skin inflammatory diseases | |
US20180303787A1 (en) | Pharmaceutical use of 3-benzylsulfonylpropionitrile | |
KR101695801B1 (ko) | 운동 뉴런의 자가 포식 작용 억제를 위한 약학적 조성물 및 이의 용도 | |
KR20190082841A (ko) | 피부 병태를 치료하기 위한 티아졸 및 코르티코스테로이드를 포함하는 조합 치료 | |
CN116265017A (zh) | 一种包含本维莫德和皮质类固醇的药物组合物 | |
CN108186558B (zh) | 一种治疗婴幼儿湿疹乳膏及其制备方法 | |
KR20190100421A (ko) | B220을 포함하는 국소 투여용 약학 제형 | |
AU2017272198A1 (en) | Sesame oil based injection formulations | |
RU2225208C1 (ru) | Фармацевтическая композиция, обладающая противовоспалительным и антиаллергическим действием | |
JP2021510159A (ja) | セルドゥラチニブ含有局所皮膚医薬組成物およびその使用 | |
EP0820289A1 (de) | Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern | |
CN115813918B (zh) | 吲哚乙酸在制备抑郁症治疗药物中的应用 | |
WO2018172496A1 (en) | Compounds and compositions for use in treating psoriasis | |
CN109939117B (zh) | 环黄芪醇在制备治疗银屑病药物中的应用 | |
RU2782133C2 (ru) | Применение фармацевтической композиции β-циклодекстрина с 9-фенил-2,3,4,5,6,7,8,9-октагидро-1Н-селеноксантеном для повышения/восстановления либидо | |
CN116262119A (zh) | 一种jak抑制剂的药物组合物 | |
TW202329976A (zh) | P13K—δ抑制劑之局部調配物 | |
WO2019111136A1 (en) | Methotrexate topical solution for treatment of psoriasis | |
CN114096314A (zh) | 痴呆症的治疗和预防药 | |
US20160030569A1 (en) | Low-glycerin formulations for hiv treatment and prevention | |
CN116019762A (zh) | 一种用于治疗银屑病的药物组合物、制备方法和用途 | |
CA2873751A1 (en) | Treatment method for steroid responsive dermatoses | |
CN110665002A (zh) | 一种用于防治牛病毒性腹泻的抗体制剂及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200513 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210708 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20211207 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220307 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220510 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220520 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7083118 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |